Search

Displaying results 2381 - 2390 of 10000 in total
  1. Drug

    Fondaparinux

    go.drugbank.com/drugs/DB00569
    ApprovedInvestigational

    Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture, hip replacement and knee surgery); to prevent VTE in … patients undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable

  2. Drug

    Ketazolam

    go.drugbank.com/drugs/DB01587
    ApprovedWithdrawn

    Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.

  3. Drug

    Etelcalcetide

    go.drugbank.com/drugs/DB12865
    ApprovedInvestigational

    Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. … Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis.

  4. Drug

    Tirbanibulin

    go.drugbank.com/drugs/DB06137
    ApprovedInvestigational

    Tirbanibulin exhibits antitumour effects in vitro and in vivo [A225791] and has been investigated for its antitumor efficacy in the management of various cancers, such as prostate cancer and breast cancer … [A225726] On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand name Klisyri.

  5. Drug

    Silver sulfadiazine

    go.drugbank.com/drugs/DB05245
    ApprovedInvestigationalVet approved

    Silver sulfadiazine is a sulfa derivative topical antibacterial used primarily on second- and third-degree burns.

  6. Drug

    Dacomitinib

    go.drugbank.com/drugs/DB11963
    ApprovedInvestigational

    [L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed. … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018.

  7. Drug

    Atomoxetine

    go.drugbank.com/drugs/DB00289
    ApprovedInvestigational

    [A18262] This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and striatum is associated with many stimulant-associated side effects and an increase in abuse potential, which … In particular, increased dopamine in key areas caused by these stimulant medications is associated with their reinforcing and addictive properties, and even amplifies the potency and reinforcing effects

  8. Drug

    Hydroflumethiazide

    go.drugbank.com/drugs/DB00774
    ApprovedWithdrawn

    A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)

  9. Drug

    Imidacloprid

    go.drugbank.com/drugs/DB11421
    ExperimentalVet approved

    It is marketed as pest control, seed treatment, an insecticide spray, termite control, flea control, and a systemic insecticide. … Imidacloprid is a neonicotinoid, which is a class of neuro-active insecticides modeled after nicotine.

    Mixtures: Advocate Spot-on Solution for Small Dogs, Advocate Spot-on Solution for Large DogsCategories: Compounds used in a research, industrial, or household setting
  10. Drug

    Benznidazole

    go.drugbank.com/drugs/DB11989
    ApprovedInvestigational

    [L939] It is the first treatment made available in the United States for Chagas disease. … Benznidazole was granted accelerated approval for the treatment of Chagas disease in children 2-12 years of age by the FDA on August 29, 2017.